#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14434	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2202	652.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1482	1482	C	818	C	775	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26640	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3700	717.9	0	.	n	.	0	T695C	SNP	695	695	T	1116	1116	C	845	C,T	802,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26640	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3700	717.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1758	1758	A	934	A,G	886,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26640	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3700	717.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2392	2392	C	857	C,G	807,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26640	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3700	717.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2466	2466	A	901	A	865	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26640	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3700	717.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3018	3018	C	751	C	725	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2166	folP	852	852	100.0	folP.l15.c30.ctg.1	1577	136.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1068	1070	AGC	217;219;220	A;G;C	203;205;206	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	172.7	1	SNP	p	S91F	0	.	.	271	273	TCC	710	712	TCC	245;245;246	T;C;C	225;226;226	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	172.7	1	SNP	p	D95G	0	.	.	283	285	GAC	722	724	GAC	239;242;243	G;A;C	223;220;225	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6140	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	172.7	1	SNP	p	D95N	0	.	.	283	285	GAC	722	724	GAC	239;242;243	G;A;C	223;220;225	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1750	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1214	142.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	361	363	ACC	193;193;191	A;C;C	177;177;179	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1750	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1214	142.9	0	.	p	.	0	R44H	NONSYN	130	132	CGC	376	378	CAC	191;197;198	C;A;C	181;181;185	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1750	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1214	142.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	559	561	CAC	257;256;252	C;A;C	244;239;238	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1750	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1214	142.9	1	SNP	p	G45D	0	.	.	133	135	GGC	379	381	GGC	199;197;198	G;G;C	181;182;186	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	920	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1083	84.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5454	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2896	187.2	1	SNP	p	D86N	0	.	.	256	258	GAC	481	483	GAC	204;206;203	G;A;C	191;189;192	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5454	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2896	187.2	1	SNP	p	S87I	0	.	.	259	261	AGT	484	486	AGT	205;205;206	A;G;T	192;195;195	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5454	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2896	187.2	1	SNP	p	S87R	0	.	.	259	261	AGT	484	486	AGT	205;205;206	A;G;T	192;195;195	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5454	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2896	187.2	1	SNP	p	S87W	0	.	.	259	261	AGT	484	486	AGT	205;205;206	A;G;T	192;195;195	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5454	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2896	187.2	1	SNP	p	S88P	0	.	.	262	264	TCC	487	489	TCC	207;206;204	T;C;C	194;193;194	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4528	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2675	168.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1551	1553	GGC	220;219;218	G;G;C	207;205;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1329	1331	GCA	227;230;227	G;C;A	212;211;215	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1332	1334	ATC	228;230;231	A;T;C	215;217;217	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1344	1346	GTG	237;240;243	G;T;G	224;221;224	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1344	1346	GTG	237;240;243	G;T;G	224;221;224	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1848	1850	ACC	195;194;199	A;C;C	179;180;187	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1902	1904	GCG	195;196;200	G;C;G	162;146;160	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1902	1904	GCG	195;196;200	G;C;G	162;146;160	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2025	2027	GGC	187;185;183	G;G;C	179;177;173	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2034	2036	GGC	178;177;176	G;G;C	167;163;164	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4196	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2582	161.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2052	2054	CCG	154;157;153	C,G;C;G	110,5;117;110	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6004	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3102	192.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2472	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1944	126.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	669	669	C	153	C	144	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	659	661	GGA	232;234;233	G;G,A;A	220;221,1;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	0	.	p	.	0	F135L	NONSYN	403	405	TTT	920	922	CTT	228;228;232	C;T;T	211;216;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	944	946	GGA	232;230;230	G;G;A	219;213;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1082	1084	AGC	234;231;230	A;G;C	220;216;216	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1148	1148	T	198	T	192	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	1	SNP	p	G120K	0	.	.	358	360	GGT	875	877	GGT	232;231;235	G,A;G,A;T,G	220,1;220,1;214,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	1	SNP	p	A121D	0	.	.	361	363	GCC	878	880	GCC	240;238;237	G,A;C,A;C	223,1;223,1;226	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2876	porB1b	1035	1035	96.19	porB1b.l15.c17.ctg.1	1705	167.8	1	SNP	p	A121N	0	.	.	361	363	GCC	878	880	GCC	240;238;237	G,A;C,A;C	223,1;223,1;226	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10476	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4855	215.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2040	2042	CAT	232;230;231	C;A;T	212;210;211	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1206	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	992	120.8	1	SNP	p	V57M	1	.	.	169	171	ATG	458	460	ATG	234;238;238	A;T;G	225;226;224	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
